CagriTirz 20mg is a dual-compound research formulation containing 10mg of cagrilintide and 10mg of tirzepatide, providing a total nominal peptide content of 20mg per vial.
Cagrilintide is a synthetic, long-acting amylin analog developed for research involving amylin-related receptor systems and peptide signaling. FDA substance records characterize cagrilintide as a 37-amino-acid amylin-analog peptide.
Tirzepatide is a synthetic peptide characterized by activity at both the glucose-dependent insulinotropic polypeptide (GIP) receptor and glucagon-like peptide-1 (GLP-1) receptor. Combining the two compounds creates a multi-target research formulation for controlled studies involving peptide characterization, receptor interactions, and related biochemical pathways.
This product is supplied specifically as a research material for controlled laboratory and analytical applications.
Product Details
- Product: CagriTirz
- Total content: 20mg
- Cagrilintide: 10mg
- Tirzepatide: 10mg
- Ratio: 1:1
- Cagrilintide classification: Amylin analog peptide
- Tirzepatide classification: Dual GIP/GLP-1 receptor agonist peptide
- Form: Dual research peptide blend
- Intended use: Laboratory and analytical research
